BR112022026747A2 - Métodos de tratamento do distúrbio do espectro da neuromielite óptica - Google Patents
Métodos de tratamento do distúrbio do espectro da neuromielite ópticaInfo
- Publication number
- BR112022026747A2 BR112022026747A2 BR112022026747A BR112022026747A BR112022026747A2 BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2 BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- nmosd
- spectrum disorders
- neuromyelitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026747A2 true BR112022026747A2 (pt) | 2023-01-24 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026747A BR112022026747A2 (pt) | 2020-06-30 | 2021-06-30 | Métodos de tratamento do distúrbio do espectro da neuromielite óptica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172211A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534916A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230030642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178954A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299381A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006283A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101977843B1 (ko) * | 2017-02-16 | 2019-05-13 | 국립암센터 | 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용 |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| EP3959241A4 (en) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE |
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
-
2021
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022006283A2 (en) | 2022-01-06 |
| MX2022016236A (es) | 2023-03-29 |
| CA3178954A1 (en) | 2022-01-06 |
| KR20230030642A (ko) | 2023-03-06 |
| EP4172211A4 (en) | 2024-07-10 |
| EP4172211A2 (en) | 2023-05-03 |
| US20230406928A1 (en) | 2023-12-21 |
| WO2022006283A3 (en) | 2022-02-03 |
| AU2021299307A1 (en) | 2022-12-22 |
| IL299381A (en) | 2023-02-01 |
| CN116234571A (zh) | 2023-06-06 |
| JP2023534916A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0922650A2 (pt) | Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina | |
| BRPI0515884A (pt) | métodos de diagnóstico e tratamento de complicações da gravidez | |
| AR080564A1 (es) | Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| BRPI0910993A2 (pt) | técnica de administração na linha de sutura usando toxinas botulínicas | |
| BR112015007144A2 (pt) | uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores | |
| BR112023019427A2 (pt) | Sistema e método para determinar um cronograma de tratamento | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| BRPI0417493B8 (pt) | uso de uma toxina botulínica para tratamento de distúrbios da pele | |
| BR112021015222A2 (pt) | Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1 | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112021024634A2 (pt) | Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno | |
| Koike et al. | Application of functional near infrared spectroscopy as supplementary examination for diagnosis of clinical stages of psychosis spectrum | |
| BR112021021141A2 (pt) | Método para modular estrutura glicocalyx endotelial | |
| JOP20230125A1 (ar) | كانابيديول لعلاج النوبات المستعصية على العلاج | |
| BR112022023928A2 (pt) | Uso de canabidiol para o tratamento do transtorno do espectro autista | |
| BR112022008886A2 (pt) | Diagnóstico de transtornos de humor usando biomarcadores de edição de rna do sangue | |
| BR112021019854A2 (pt) | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares | |
| Zhang et al. | Knockdown of OLA1, a regulator of oxidative stress response, inhibits motility and invasion of breast cancer cells | |
| Kalotra et al. | 5‐Nonyloxytryptamine oxalate–embedded collagen–laminin scaffolds augment functional recovery after spinal cord injury in mice | |
| Simhadri et al. | Dysregulation of LIMK‐1/cofilin‐1 pathway: a possible basis for alteration of neuronal morphology in experimental cerebral malaria | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos | |
| Suto et al. | Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition | |
| MX2022016236A (es) | Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. | |
| Isik et al. | SIRT1, MMP-9 and TIMP-1 levels in children with specific learning disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: VIELA BIO, INC. (US) |